Sanofi shells out $11.6bn on Bioverativ
Sanofi is fortifying its presence in the field of blood disorders through the purchase of Bioverativ in a deal valued at some $11.6 billion.
Read More
Tag: Bioverative
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
